Patient Centered Approaches to Preventing ASCVD Events

以患者为中心的预防 ASCVD 事件的方法

• 批准号: 10323260
• 负责人: SAMIA MORA
• 金额: $ 12.05万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-01-01 至 2023-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10323260
• 关键词: Achievement; Address; Age; American Heart Association; Apolipoproteins B; Atherosclerosis; Automobile Driving; Award; Biological Markers; Blood Vessels; Cardiovascular Diseases; Cardiovascular system; Center for Translational Science Activities; Clinical; Collaborations; Coupling; Data; Diagnostic; Dimensions; Disease; Dyslipidemias; Education; Environment; Epidemiology; Event; Goals; Hospitals; IDL lipoproteins; Individual; Institution; Insulin Resistance; International; Investigation; LDL Cholesterol Lipoproteins; Lead; Lipids; Lipoproteins; Low-Density Lipoproteins; Measures; Mentors; Methods; Modernization; Molecular; Myocardial Infarction; Outcome; Participant; Pathway interactions; Patients; Pharmaceutical Preparations; Phenotype; Population; Postdoctoral Fellow; Prevention; Prevention Research; Preventive Medicine; Preventive therapy; Research; Research Activity; Research Personnel; Research Project Grants; Residual state; Resources; Risk; Risk Assessment; Risk Factors; Risk Management; Role; Science; Sum; Teaching Hospitals; Testing; Training; United Arab Emirates; Very low density lipoprotein; Woman; Women' s Health; Work; atherosclerosis risk; cardiovascular disorder prevention; cardiovascular disorder risk; cardiovascular health; cardiovascular risk factor; career; career development; case control; cost; cost effective; early onset; experience; high risk; high risk population; improved; inhibitor; instrumentation; interest; lipoprotein triglyceride; medical schools; men; modifiable risk; mortality; multidisciplinary; novel; novel marker; novel therapeutic intervention; particle; patient oriented; patient oriented research; patient population; personalized medicine; pre-doctoral; premature; prevent; programs; prospective; recruit; research clinical testing; risk prediction; therapeutic target; training opportunity; young adult; young woman

7. Project Summary/Abstract As a cardiologist cross-trained in epidemiology, Dr. Mora has devoted her career to patient-oriented cardiovascular prevention research, focusing on modifiable risk factors, particularly lipids. Her independent contributions to the field of prevention resulted from a succession of in-depth studies examining the clinical utility of alternative lipid testing for cardiovascular risk prediction and management. She has served as a primary research mentor for more than twenty pre- and post-doctoral trainees in patient- oriented research projects. This has been highlighted in recent years by the achievements of her mentees in presenting their work nationally and internationally, with recognition by the American Heart Association Young Investigator Award and Best of Science abstract sessions. At the national level, Dr. Mora has also been active in promoting cardiovascular careers for women postdoctoral fellows. The candidate's experienced Mentoring Committee, ongoing patient-oriented research, exceptional institutional resources, and cost-effective collaborations provide a nurturing environment for the training and career development of junior investigators in patient-oriented cardiovascular disease research. The new research aims proposed in this award will evaluate lipid-related risk of atherosclerotic cardiovascular disease (ASCVD) among two populations of patients: those who are treated with statins and those who suffer from premature myocardial infarction. This has important clinical implications as new therapeutic strategies targeting lipids are rapidly emerging and already in clinical use. Currently, statin therapy is the cornerstone of dyslipidemia management and cardiovascular prevention and treatment. However, the majority of events (70%) among statin-treated individuals remain unprevented and common (1 in 7 statin-treated individuals). To this date, the mechanisms underlying this “residual risk” are unclear. While it is commonly believed that the risk factors responsible for ASCVD events among statin- treated individuals are the same as those among statin-naïve individuals, new data suggest there may be differences. Furthermore, while overall ASCVD mortality has declined in the US in the past decade, there has been no decrease or even an increase in mortality in younger adults recently, in particular for women. The impact of the study is to improve clinical outcomes by identifying lipid-related determinants of vascular risk and to grow and strengthen Dr. Mora's patient-oriented research program into a formal individualized program of mentoring with a focus on lipid risk factors. In sum, the proposed mentoring and research activities of this K24 project will provide numerous excellent training opportunities for junior investigators interested in patient- oriented cardiovascular research.

7.项目摘要/摘要作为一名接受过流行病学交叉培训的心脏病专家，莫拉博士致力于 职业生涯以患者为导向的心血管预防研究，重点是可改变的风险因素，特别是 脂质。她对预防领域的独立贡献来自于一系列深入的研究 检查替代血脂检测对心血管风险预测和管理的临床效用。她 曾担任二十多名博士前和博士后实习生的主要研究导师，从事患者- 定向研究项目。近年来，她的学员在以下方面的成就突出了这一点： 在国内和国际上展示他们的工作，并获得美国心脏协会的认可。 研究者奖和最佳科学摘要会议。在国家一级，莫拉博士也一直积极参与 在促进女性博士后研究员的心血管事业。候选人经验丰富的指导 委员会，正在进行的以病人为导向的研究，特殊的机构资源，和成本效益 合作为初级调查员的培训和职业发展提供了有利的环境， 以病人为中心的心血管疾病研究。该奖项提出的新研究目标将评估 在两个患者人群中，脂质相关的动脉粥样硬化性心血管疾病（ASCVD）风险： 他汀类药物治疗和过早心肌梗死患者。这具有重要 作为靶向脂质的新治疗策略的临床意义正在迅速出现，并且已经在临床上应用。 使用.目前，他汀类药物治疗是血脂异常管理和心血管疾病预防的基石 和治疗。然而，他汀类药物治疗个体中的大多数事件（70%）仍然无法预防 常见（1/7他汀类药物治疗个体）。到目前为止，这种“残余风险”背后的机制是 不清楚虽然通常认为他汀类药物中ASCVD事件的危险因素- 治疗的个体与他汀类药物初治个体相同，新的数据表明， 差异此外，尽管在过去十年中美国的总体ASCVD死亡率有所下降， 最近，年轻人，特别是妇女的死亡率没有下降，甚至有所上升。的 该研究的影响是通过识别血管风险的脂质相关决定因素来改善临床结局， 发展和加强莫拉博士以病人为导向的研究计划，使之成为一个正式的个性化计划， 指导重点是血脂风险因素。总而言之，K24的建议指导和研究活动 该项目将为对患者感兴趣的初级研究人员提供许多极好的培训机会， 心血管研究方向。